IBI310 + SINTILIMAB + SURUFATINIB for neuroendocrine tumors

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Dec 2021: Trial registered, NCT05165407
  2. 12 Jul 2022: Trial started, NCT05165407

The trials

NCT05165407: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

State
Under way
Phase
Phase 2
People
30 planned
Started
12 Jul 2022
Primary completion
Sep 2025
Arms
Sintilimab Combined With IBI310 and Surufatinib
Results
None posted
  1. 21 Dec 2021: Trial registered
  2. 12 Jul 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.